Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Research & Development (2019 - 2025)

BridgeBio Pharma's Research & Development history spans 7 years, with the latest figure at $116.4 million for Q4 2025.

  • For Q4 2025, Research & Development fell 10.69% year-over-year to $116.4 million; the TTM value through Dec 2025 reached $452.0 million, down 10.76%, while the annual FY2025 figure was $452.0 million, 10.76% down from the prior year.
  • Research & Development for Q4 2025 was $116.4 million at BridgeBio Pharma, up from $112.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $141.0 million in Q1 2024 and bottomed at $90.9 million in Q4 2022.
  • The 5-year median for Research & Development is $112.2 million (2025), against an average of $113.2 million.
  • The largest annual shift saw Research & Development soared 79.64% in 2021 before it fell 25.61% in 2022.
  • A 5-year view of Research & Development shows it stood at $122.2 million in 2021, then dropped by 25.61% to $90.9 million in 2022, then skyrocketed by 43.26% to $130.2 million in 2023, then grew by 0.1% to $130.4 million in 2024, then fell by 10.69% to $116.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Research & Development are $116.4 million (Q4 2025), $112.9 million (Q3 2025), and $111.2 million (Q2 2025).